For US residents only

Understanding Treatment

TYKERB + capecitabine

TYKERB plus capecitabine

TYKERB® (lapatinib) plus capecitabine is used to treat women with HER2+ advanced or metastatic breast cancer who have had treatment with:

  • Herceptin® (trastuzumab)
  • An anthracycline, such as Adriamycin® (doxorubicin)
  • A taxane, such as Taxol® (paclitaxel) or Taxotere® (docetaxel)

Metastatic breast cancer is when the cancer has spread from the original site in the breast to other places in the body.

 

TYKERB plus capecitabine may slow the progression of HER2+ metastatic breast cancer in some women after therapy with these treatments—trastuzumab, an anthracycline, or a taxane—has been completed. Go to the How Treatment May Help section for more information about the benefits of treatment. Please view the Side Effects section for more information about potential risks of TYKERB plus capecitabine.

 

TYKERB is an oral therapy. Unlike other medications you may have had for your HER2+ metastatic breast cancer, TYKERB is not given at the doctor’s office. It is a pill you take by mouth.

How does TYKERB work?

How Does TYKERB Work

 

 

TYKERB is designed to inhibit HER2 receptors:

  • HER2 is a type of protein found on normal cells, as well as breast cancer cells
  • In women with HER2+ breast cancer, the breast cancer cells have too many HER2 receptors (designated as HER2+)
  • When these HER2 receptors join together, they direct cancer cells to grow and divide
  • TYKERB works inside cancer cells to block HER2 receptors
  • TYKERB is a small molecule that passes through the surface of cells
  • Once inside the cell, TYKERB binds to the HER2 protein receptor inside the cell and may help block HER2 receptor activity

When tested in animals and in human breast cancer cells grown outside the body, TYKERB blocked HER2 receptors and cell growth.